Galmed Pharmaceuticals (GLMD) Amortization (2022 - 2024)

Galmed Pharmaceuticals' Amortization history runs 3 years deep, the most recent figure standing at -$93000.0 for Q3 2024.

• In Q3 2024, Amortization fell 69.09% year-over-year to -$93000.0; the TTM figure through Mar 2023 stood at $5000.0 (changed N/A YoY), while the FY2022 annual figure was $1000.0, changed N/A from the prior year.
• Amortization was -$93000.0 for Q3 2024 at Galmed Pharmaceuticals, down from -$55000.0 in the prior quarter.
• In the past five years, Amortization ranged from a high of $5000.0 in Q1 2023 to a low of -$93000.0 in Q3 2024.
• Historically, Amortization has averaged -$35500.0 across 3 years, with a median of -$27000.0 in 2022.
• Biggest YoY gain for Amortization was 69.09% in 2024; the steepest drop was 69.09% in 2024.
• A 3-year view of Amortization shows it stood at $1000.0 in 2022, then plunged by 5600.0% to -$55000.0 in 2023, then tumbled by 69.09% to -$93000.0 in 2024.
• The last three Amortization figures came in at -$93000.0 (Q3 2024), -$55000.0 (Q3 2023), and $5000.0 (Q1 2023), per Business Quant data.